Search

Displaying results 3261 - 3270 of 10000 in total
  1. Drug

    Potassium guaiacolsulfonate

    go.drugbank.com/drugs/DB13735
    ApprovedWithdrawn

    Guaiacolsulfonate is an aromatic sulfonic acid. Potassium guaiacolsulfonate salt is an expectorant that thins the mucus in the lungs and reduces chest congestion.

  2. Drug

    IGN101

    go.drugbank.com/drugs/DB06500
    Experimental

    IGN101 is an antibody-based cancer vaccine directed against epithelial cancers. It consists of 500 ug 17-1A antibody adsorbed on aluminum hydroxide.

  3. Drug

    RAV12

    go.drugbank.com/drugs/DB05140
    Investigational

    RAV12 is a chimeric antibody that recognizes RAAG12, an N-linked carbohydrate antigen found on gastric, colon, pancreatic, prostate, ovarian, breast, and kidney cancer cells. … RAV12 is investigated for use/treatment in solid tumors. RAV12 is a solid.

  4. Drug

    Silanol

    go.drugbank.com/drugs/DB11343
    Approved

    Silanol is an FDA-approved food contact substance that is commonly used in organosilicon chemistry and silicate mineralogy.

  5. Drug

    Meplazumab

    go.drugbank.com/drugs/DB16465
    Investigational

    Meplazumab is a humanized anti-CD147 antibody being investigated as an add-on therapy in patients with COVID-19 pneumonia.

  6. Drug

    Rumex acetosella whole

    go.drugbank.com/drugs/DB14166
    ApprovedWithdrawn

    Rumex acetosella whole allergenic extract is used in allergenic testing.

  7. Drug

    Rumex crispus top

    go.drugbank.com/drugs/DB14167
    ApprovedWithdrawn

    Rumex crispus top allergenic extract is used in allergenic testing.

  8. Drug

    Salix nigra bark

    go.drugbank.com/drugs/DB14169
    ApprovedWithdrawn

    Salix nigra bark allergenic extract is used in allergenic testing.

  9. Drug

    Arbaclofen Placarbil

    go.drugbank.com/drugs/DB08892
    Investigational

    by XenoPort in 2011 for the treatment of GERD. … On May 20th, 2013, XenoPort announced plans to terminate the development of Arbaclofen Placerbil for the treatment of multiple sclerosis.

  10. Drug

    Sonrotoclax

    go.drugbank.com/drugs/DB18753
    ApprovedInvestigational

    Sonrotoclax is a selective, potent, small-molecule inhibitor of BCL-2, an antiapoptotic protein overexpressed in B-cell malignancies. … [L56193,L56194] The application received priority review, breakthrough therapy designation, and orphan drug designation, and was reviewed under Project Orbis with the EMA as an official observer.

    Synonyms: N-[4-({[(1r,4r)-4-hydroxy-4-methylcyclohexyl]methyl}amino)-3- nitrobenzene-1-sulfonyl]-4-(2-{(2S)-2-[2-(propan-2-yl)phenyl]pyrrolidin- 1-yl}-7-azaspiro[3.5]nonan-7-yl)-2-[(1H-pyrrolo[2,3-b]pyridin-5- yl